Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference

LEXINGTON, Mass.--(Business Wire)--
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Robert Perez,
EVP and COO, will present on Wednesday, November 18, 2009 at 1:45 p.m. Eastern
Time at the Lazard Capital Markets 6th Annual Healthcare Conference at the St
Regis Hotel in New York City. This presentation will include discussion of the
company`s business activities, financial outlook, and current news.

A live webcast of the presentation will be accessible through Cubist`s website
at www.cubist.com in the Investor Relations Conference Calendar section. The
webcast will be available on Cubist`s website for a period of 30 days after the
presentation.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address unmet medical needs in the acute care environment. In the U.S., Cubist
markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class
of anti-infectives called lipopeptides. In July 2008, Cubist began promoting
MERREM® I.V. (meropenem for injection) in the United States. MERREM is an
established broad spectrum antibiotic developed by AstraZeneca. The Cubist
product pipeline includes ecallantide, a recombinant human protein in Phase 2
clinical trials - CONSERV-1 and CONSERV-2 - for the reductionof blood loss
during cardiac surgery, and two Phase 1 programs that address unmet medical
needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in
multi-drug resistant (MDR) Gram-negative infections. In addition, the Company,
in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a
pre-IND and a Phase 2 program underway in novel treatments for respiratory
syncytial virus infections using Alnylam`s RNA-interference technology. Cubist
is headquartered in Lexington, MA. Additional information can be found at
Cubist`s web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of
companies.

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Corporate Communications
eileen.mcintyre@cubist.com
or
Weber Shandwick
Tara Murphy, 617-520-7045
tara.murphy@webershandwick.com

Copyright Business Wire 2009